Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 0.54 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.54 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.54 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.50 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133218 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL9742724 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL9165530 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL27550353 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL1356398 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL462454 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL1322462 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL7117013 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL7171543 | 0.96 | ITPR3 (0.60) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL11233751 | 0.96 | ITPR3 (0.60) | ITPR3ITPR1ITPR2INPP5ASMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368948-A1 | PRODUCT, SYSTEM AND METHOD OF CELL CULTIVATION | BTL Healthcare Technologies a,s. | 2025-12-04 | — | — | US | claimed |
| CN-119352003-A | Aluminum pop can cover material passivating agent for water-based paint and preparation method thereof | 广州和力表面处理技术有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119310212-A | Liquid quality method for rapidly detecting phytic acid and degradation products thereof in underground water | 中国矿业大学 | 2025-01-14 | — | — | CN | claimed |
| EP-3699271-B1 | GRANULE AND PELLET COMPOSITIONS COMPRISING PHYTASE AND PHYTIC ACID AND PREPARATION METHOD | DANISCO US INC (US) | 2024-09-25 | — | — | EP | claimed |
| CN-112135791-B | Organically modified mineral particles, method for the production and use thereof | 禾大国际股份公开有限公司 | 2024-01-26 | — | — | CN | claimed |
| EP-3974454-B1 | METHOD FOR PREPARING HIGH-PURITY SUGAMMADEX SODIUM | HEFEI BOSIKC PHARMTECH CO LTD (CN) | 2024-01-10 | — | — | EP | claimed |
| US-20220249521-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | Sanifit Therapeutics S.A. (ES) | 2022-08-11 | — | — | US | claimed |
| CN-112851833-B | Purification method for reducing protein content in sodium hyaluronate and derivatives thereof | 合肥博思科创医药科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| US-11306158-B1 | Method for preparing high-purity sugammadex sodium | HEFEI BOSIKC PHARMTECH CO., LTD. (CN) | 2022-04-19 | — | — | US | claimed |
| EP-3974454-A1 | METHOD FOR PREPARING HIGH-PURITY SUGAMMADEX SODIUM | Hefei Bosikc Pharmtech Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-0180581-B1 | DRUG PREPARATIONS OF REDUCED TOXICITY | THE LIPOSOME COMPANY, INC. (US) | 1991-08-07 | — | — | EP | claimed |
| EP-0179441-B1 | A METHOD OF MAKING A FOOD COMPOSITION CONTAINING INOSITOLTRIPHOSPHATE AND THE COMPOSITION | Sirén, Matti (CH) | 1989-04-05 | — | — | EP | claimed |
| EP-0180581-A4 | DRUG PREPARATIONS OF REDUCED TOXICITY. | LIPOSOME CO INC (US) | 1988-04-27 | — | — | EP | claimed |
| US-4734283-A | REMOVAL OF CADMIUM FROM BODY | PERSTORP AB (SE) | 1988-03-29 | — | — | US | claimed |
| US-4652449-A | Encapsulating biological active substances into erythrocytes | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1987-03-24 | — | — | US | claimed |
| EP-0180581-A1 | DRUG PREPARATIONS OF REDUCED TOXICITY. | LIPOSOME CO INC (US) | 1986-05-14 | — | — | EP | claimed |
| EP-0179441-A2 | A method of making a food composition containing inositoltriphosphate and the composition | Sirén, Matti (CH) | 1986-04-30 | — | — | EP | claimed |
| WO-1985005030-A1 | DRUG PREPARATIONS OF REDUCED TOXICITY | THE LIPOSOME COMPANY, INC. (US) | 1985-11-21 | — | — | WO | claimed |
| US-4321259-A | Controlled improvement of the O2 -release by intact erythrocytes | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 1982-03-23 | — | — | US | claimed |
| EP-0001104-B1 | MODIFIED INTACT ERYTHROCYTES, BLOOD OR BLOOD PRESERVES CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | Studiengesellschaft Kohle mbH (DE) | 1981-05-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249521-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | ATP6V1B1, PROC, GC | ITPR3 129/4885ITPR1 168/4885ITPR2 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.